Autacoids And Related Drug Global Market Report 2025

The autacoids and related drug market size has grown strongly in recent years. It will grow from $50.15 billion in 2024 to $53.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to several factors, including the increasing prevalence of inflammatory diseases, a rising use of prostaglandins in obstetrics, widespread prescription of antihistamines, the expanding applications of serotonin agonists, and higher demand for migraine relief medications.

The autacoids and related drug market size is expected to see strong growth in the next few years. It will grow to $67.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to several factors, including the rising geriatric population, growing prevalence of chronic respiratory diseases, adoption of personalized medicine, expanding healthcare access in emerging economies, and the increasing incidence of cardiovascular disorders. Key trends during this period include the integration of artificial intelligence in drug discovery, the development of dual-action autacoid drugs, the adoption of biosimilars for autacoid treatments, growth in self-medication and over-the-counter (OTC) products, and the use of nanotechnology in drug formulation.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the autacoids and related drugs market in the coming years. Cardiovascular diseases encompass a range of disorders that impact the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. The rise in cardiovascular diseases is mainly linked to poor dietary habits, with high consumption of saturated fats, trans fats, added sugars, and sodium contributing to high blood pressure, obesity, and elevated cholesterol levels, all of which are significant risk factors for heart-related conditions. Autacoids and related drugs support cardiovascular health by modulating vascular tone and inflammation, both of which are critical in managing hypertension and heart failure. Agents that target pathways involving nitric oxide, endothelin, and prostacyclin aid in restoring endothelial function, promoting vasodilation, and reducing vascular resistance. For instance, in December 2023, the Australian Institute of Health and Welfare reported that the number of doctor-certified deaths due to coronary heart disease (CHD) in Australia rose from 14,100 in 2021 to 14,900 in 2022. Consequently, the increasing prevalence of cardiovascular diseases is fueling the growth of the autacoids and related drugs market.

Leading companies in the autacoids and related drugs market are concentrating on the development of innovative products, such as antihistamines, to enhance therapeutic effectiveness, reduce side effects, and address new allergic and inflammatory conditions with greater accuracy and safety. Antihistamines are medications that block the effects of histamine, a chemical released by the immune system during an allergic reaction. For example, in March 2023, Tiefenbacher Pharmaceuticals, a Germany-based pharmaceutical company, launched Bilastine as an over-the-counter (OTC) medication in Germany, representing a significant advancement in improving access to effective allergy treatments. The 20 mg Bilastine tablets offer a non-sedating, second-generation antihistamine solution for individuals experiencing allergic symptoms such as hay fever and urticaria.

In May 2024, Incyte Corporation, a US-based biopharmaceutical company, completed the acquisition of Escient Pharmaceuticals Inc. for approximately $750 million. This acquisition enables Incyte to expand its immunology portfolio and accelerate the development of novel treatments for pruritus and other inflammatory disorders by integrating Escient Pharmaceuticals' innovative pipeline of first-in-class, small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs). Escient Pharmaceuticals Inc., a US-based biotechnology company, is focused on developing novel therapeutics that target autacoid-related pathways.

Major players in the autacoids and related drug market are Sanofi S.A., Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Limited, EUROAPI S.A., Pfizer CentreOne, Cayman Chemical Company, Tokyo Chemical Industry Co. Ltd., Avanti Polar Lipids Inc., Kyowa Pharma Chemical Co. Ltd., Nicox S.A., Glentham Life Sciences Ltd., LGM Pharma Inc., chemBlink Inc., ZellBio GmbH, AquigenBio LLC, BOC Sciences Inc., Yarrow Chem Products Pvt. Ltd., LEBSA S.A., VDK NaturaSyn S.A., Enzo Life Sciences Inc.

North America was the largest region in the autacoids and related drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autacoids and related drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autacoids and related drugsmarket report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Autacoids and related drugs are biologically active substances produced by the body that regulate physiological functions locally, typically within specific tissues or organs. They play a role in inflammation, smooth muscle contraction, immune responses, and the regulation of blood flow. Autacoids exert their effects by binding to specific receptors on target cells, triggering signaling pathways that influence cellular activity.

The main types of autacoids and related drugs include histamines, prostaglandins, leukotrienes, serotonin, and bradykinin. Histamines are chemicals released during allergic reactions that lead to symptoms such as itching, swelling, and increased stomach acid. They are targeted in treatments for allergies and acid-related conditions. Drugs aimed at these autacoids can be administered through various routes, such as oral, injectable, topical, intranasal, and inhalation. These treatments are used for a range of applications, including cardiovascular disorders, inflammatory diseases, respiratory disorders, allergies, and gastrointestinal conditions. The primary end users of these treatments include hospitals, clinics, homecare settings, and pharmacies.

The autacoids and related drug market research report is one of a series of new reports that provides autacoids and related drug market statistics, including the autacoids and related drug industry global market size, regional shares, competitors with the autacoids and related drug market share, detailed autacoids and related drug market segments, market trends, and opportunities, and any further data you may need to thrive in the autacoids and related drug industry. This autacoids and related drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autacoids and related drug market consists of sales of biogenic amines, polypeptide autacoids, lipid-derived autacoids, and leukotrienes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.